FRA
HAE icon

Front Row Advisors’s Haemonetics HAE Stock Holding History

Front Row Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-61
Closed -$7K – 967
2019
Q2 		$7K Hold
61
– – 0.01% 505
2019
Q1 		$5K Hold
61
– – ﹤0.01% 581
2018
Q4 		$6K Hold
61
– – 0.01% 498
2018
Q3 		$6 Buy
61
+23
+61% +$2.38K ﹤0.01% 513
2018
Q2 		$4 Buy
+38
New +$3.21K ﹤0.01% 667

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Front Row Advisors's HAE Position: Q3 2019 in Review

Front Row Advisors sold out of Haemonetics (HAE) in Q3 2019, closing a stake of 61 shares — an estimated $7K sold.

Front Row Advisors first reported a position in HAE in Q2 2018 and held it in 5 quarters. The position peaked at $7K in Q2 2019. 275 funds tracked by Wall St. Rank hold HAE as of Q3 2019.

  • Front Row Advisors reported no remaining Haemonetics position as of Q3 2019 after selling out during the quarter.
  • Front Row Advisors sold 61 Haemonetics shares in Q3 2019, an estimated $7K.
  • Front Row Advisors first reported a position in Haemonetics in Q2 2018 and held it in 5 quarters.
  • Front Row Advisors's Haemonetics position peaked at $7K in Q2 2019.
  • 275 funds tracked by Wall St. Rank held Haemonetics as of Q3 2019.

Based on Front Row Advisors's 13F filing for Q3 2019, filed 8 Nov 2019.